Cargando…
Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
The integrase (IN) strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), comprise the newest drug class approved for the treatment of HIV-1 infection, which joins the existing classes of reverse transcriptase, protease and binding/entry inhibitors. The ef...
Autores principales: | White, Kirsten L., Raffi, Francois, Miller, Michael D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113796/ https://www.ncbi.nlm.nih.gov/pubmed/25054884 http://dx.doi.org/10.3390/v6072858 |
Ejemplares similares
-
Multiple choices for HIV therapy with integrase strand transfer inhibitors
por: Raffi, Francois, et al.
Publicado: (2012) -
Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania
por: Henerico, Shimba, et al.
Publicado: (2022) -
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome
por: Abram, Michael E., et al.
Publicado: (2017) -
Transmitted Drug Resistance Against Integrase Strand Transfer Inhibitors in Iranian HIV-Infected Naïve Patients
por: Hashempour, Ava, et al.
Publicado: (2023) -
HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)